Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs for patients with a poor PS remains unknown. It was hypothesized that a poor Eastern Cooperative Oncology Group (ECOG) PS (≥2 vs 0-1) would correlate with shorter overall survival (OS) in patients receiving ICIs.

Related collections

Author and article information

Journal

Title: Cancer

Abbreviated Title: Cancer

Publisher: Wiley

ISSN (Print): 0008-543X

ISSN (Electronic): 1097-0142

Publication date Created: December 24 2019

Publication date Created: March 15 2020

Publication date (Electronic): December 12 2019

Publication date (Print): March 15 2020

Volume: 126

Issue: 6

Pages: 1208-1216

Affiliations

[1 ]Division of Oncology Department of Medicine University of Washington Seattle Washington

[2 ]Division of Hematology Department of Medicine University of Washington Seattle Washington

[3 ]Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University Atlanta Georgia

[4 ]Department of Medicine University of Utah Salt Lake City Utah

[5 ]Vall d'Hebron Institute of Oncology, Vall d'Hebron University HospitalAutonomous University of Barcelona Barcelona Spain

[6 ]Division of Hematology/Oncology Department of Medicine University of Virginia School of Medicine Charlottesville Virginia

[7 ]Division of Hematology/Oncology Department of Medicine Case Comprehensive Cancer Center Cleveland Ohio

[8 ]Department of Medical Oncology Montefiore Medical Center Bronx New York

[9 ]Department of Urology Montefiore Medical Center Bronx New York

[10 ]Section of Hematology Oncology Department of Medicine University of Oklahoma Stephenson Cancer Center Oklahoma City Oklahoma

[11 ]Medical Oncology Department Hospital del Mar Research Institute Barcelona Spain

[12 ]Department of Surgery and Cancer Imperial College London London United Kingdom

[13 ]Division of Hematology/Oncology David Geffen School of Medicine University of California Los Angeles Los Angeles California

[14 ]Division of Hematology/Oncology Department of Medicine Penn State Cancer Institute Hershey Pennsylvania

[15 ]Department of Oncology Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland

[16 ]Marques de Valdecilla University Hospital, Instituto de Investigacion Sanitaria Valdecilla Santander Spain

[17 ]Department of Medicine and Oncology Tulane University New Orleans Louisiana

[18 ]Department of Medicine University of Iowa Iowa City Iowa

[19 ]Department of Oncology and Nuclear Medicine University Hospital Center, Sisters of Charity Zagreb School of Medicine Zagreb Croatia

[20 ]College of Medicine Drexel University Philadelphia Pennsylvania

[21 ]Division of Oncology Department of Medicine University of Iowa Iowa City Iowa

[22 ]Division of Oncology, Department of Medicine Icahn School of Medicine at Mount Sinai New York New York

[23 ]Genitourinary Oncology Program Dana‐Farber Cancer Institute Harvard Medical School Boston Massachusetts

[24 ]Public Health Sciences Division Fred Hutchinson Cancer Research Center Seattle Washington

Article

DOI: 10.1002/cncr.32645

PMC ID: 7050422

PubMed ID: 31829450

SO-VID: bb0af7cf-3bcb-410e-ba33-6805e800c226

License:

http://onlinelibrary.wiley.com/termsAndConditions#vor

http://doi.wiley.com/10.1002/tdm_license_1.1

History

Data availability:

Comments

Comment on this article

scite_

Cited by 39

See all cited by